Literature DB >> 10854233

Genetic progression and divergence in pancreatic carcinoma.

M Yamano1, H Fujii, T Takagaki, N Kadowaki, H Watanabe, T Shirai.   

Abstract

Genetic alterations of pancreatic intraductal lesions adjacent to invasive ductal carcinoma were investigated. We submitted nine foci of ordinary epithelium, 12 foci of nonpapillary hyperplasia, 12 foci of papillary hyperplasia (pap HP), 66 foci of severe ductal dysplasia, and 27 invasive foci from a total of 10 pancreatic carcinomas for genetic analysis. All foci were individually microdissected and allelic losses of 3p, 4q, 5q, 6q, 8p, 9p, 10q, 11q, 13q, 16q, 17p, and 18q were studied. All invasive and severely dysplastic intraductal foci exhibited loss of heterozygosity (LOH) at more than one chromosomal locus. For each case, allelic loss was frequently observed on 9p (severe ductal dysplasia 90%, invasion 100%), 17p (severe ductal dysplasia 80%, invasion 80%), and 18q (severe ductal dysplasia 88%, invasion 88%). Ninety-four percent of severe ductal dysplasia and 96% of invasive foci had multiple LOH. Seventeen percent of nonpapillary hyperplasia and 33% of pap HP showed LOH. Only one focus of pap HP showed multiple LOH. The patterns of allelic loss identified in severe ductal dysplasia were generally conserved in synchronous infiltrating tumors, supporting the paradigm that infiltrating tumors are clonally derived from severe ductal dysplasia. In eight of 10 cases, however, we found frequent genetic heterogeneity in the intraductal lesion, suggestive of genetic progression or diversion. These findings indicate that invasive pancreatic carcinoma evolves through successive and divergent genetic changes with selection of aggressive subclones in the intraductal component.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854233      PMCID: PMC1850062          DOI: 10.1016/S0002-9440(10)65083-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections.

Authors:  C A Moskaluk; S E Kern
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.

Authors:  C A Moskaluk; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

3.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

Review 4.  Japan Pancreatic Cancer Registry: current status.

Authors:  M Yamamoto; O Ohashi; Y Saitoh
Journal:  Pancreas       Date:  1998-04       Impact factor: 3.327

5.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.

Authors:  H Fujii; R Szumel; C Marsh; W Zhou; E Gabrielson
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

7.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

8.  Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer.

Authors:  A B McKie; M I Filipe; N R Lemoine
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

9.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

Authors:  M Tada; M Ohashi; Y Shiratori; T Okudaira; Y Komatsu; T Kawabe; H Yoshida; R Machinami; K Kishi; M Omata
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

Review 10.  Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases.

Authors:  P M Pour; S Sayed; G Sayed
Journal:  Am J Clin Pathol       Date:  1982-02       Impact factor: 2.493

View more
  43 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis.

Authors:  N Howes; J P Neoptolemos
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

4.  Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

Authors:  David Roife; Ya'an Kang; Li Wang; Bingliang Fang; Stephen G Swisher; Jeffrey E Gershenwald; Shanna Pretzsch; Colin P Dinney; Matthew H G Katz; Jason B Fleming
Journal:  Surgery       Date:  2017-01-09       Impact factor: 3.982

Review 5.  Pancreatic stem cells: differentiation options.

Authors:  M Sambasiva Rao; Janardan K Reddy
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

6.  Detection of oncogenes in chronic pancreatitis.

Authors:  D Paramythiotis; J Kleeff; J Schmidt; M W Büchler; H Friess
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

7.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

8.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

9.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

10.  Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.

Authors:  Jan Franko; Alyssa M Krasinskas; Marina N Nikiforova; Narcis O Zarnescu; Kenneth K W Lee; Steven J Hughes; David L Bartlett; Herbert J Zeh; A James Moser
Journal:  J Gastrointest Surg       Date:  2008-08-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.